Monday, December 3, 2012
Publicity, regulation tightening reins on use of KOLs
BioCryst Pharmaceuticals, a biopharmaceutical company focused on infectious and inflammatory diseases, and privately held Presidio Pharmaceuticals, a San Francisco-based clinical stage specialty pharmaceutical company focused on small molecule antiviral therapeutics, have agreed to the mutual termination of their Merger Agreement and the related Investor Financing Agreement entered into on October 17, 2012.
Researchers at the University of Georgia have discovered that a virus commonly found in dogs may serve as the foundation for the next great breakthrough in human vaccine development.
Selecta Biosciences, a Watertown, Mass.-based clinical-stage biopharmaceutical company developing a new class of synthetic vaccines and immunotherapies, has entered into a strategic global collaboration with global healthcare company Sanofi to discover highly targeted, antigen-specific immunotherapies for life-threatening allergies.
Rib-X Pharmaceuticals, a New Haven, Conn.-based biopharmaceutical company developing new antibiotics to treat serious and life-threatening infections, has closed the first tranche of a $67.5 million Series 2 preferred stock financing. A second tranche is anticipated to close around the end of 2012.